Literature DB >> 23146920

Evaluation of SOX9 expression in pancreatic ductal adenocarcinoma and intraductal papillary mucinous neoplasm.

Takayuki Tanaka1, Tamotsu Kuroki, Tomohiko Adachi, Shinichiro Ono, Masataka Hirabaru, Akihiko Soyama, Amane Kitasato, Mitsuhisa Takatsuki, Tomayoshi Hayashi, Susumu Eguchi.   

Abstract

OBJECTIVES: Sex-determining region Y (SRY) box 9 (SOX9) is an important transcription factor required for development and has been implicated in several types of cancer. Sex-determining region Y box 9 has never been linked to pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasm (IPMN) of the pancreas. The aim of this study was to investigate the relationship between SOX9 and PDAC and that between SOX9 and IPMN.
METHODS: Surgical specimens were obtained from 55 patients with PDAC and 68 patients with IPMN and were investigated using SOX9 immunohistochemical analysis.
RESULTS: The rate of SOX9 positive cells to total pancreatic duct epithelial cells in a normal pancreas was 82.7%. On the other hand, the SOX9 positive rate in PDAC was 0.8%. There was a significant difference between the normal pancreas and PDAC (P = 0.0002). In IPMN, the SOX9 positive rate gradually decreased according to tumor progression, with the following rates observed: intraductal papillary mucinous adenoma (66.3%); noninvasive intraductal papillary mucinous carcinoma (46.3%); minimally invasive intraductal papillary mucinous carcinoma (30.5%); and invasive carcinoma originating in intraductal papillary mucinous carcinoma (2.3%). There were significant differences between each group (P < 0.05).
CONCLUSIONS: Our data suggested that SOX9 might contribute to carcinogenesis in PDAC and IPMN.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23146920     DOI: 10.1097/MPA.0b013e318269d281

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  10 in total

1.  The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.

Authors:  Guido von Figura; Akihisa Fukuda; Nilotpal Roy; Muluye E Liku; John P Morris Iv; Grace E Kim; Holger A Russ; Matthew A Firpo; Sean J Mulvihill; David W Dawson; Jorge Ferrer; William F Mueller; Anke Busch; Klemens J Hertel; Matthias Hebrok
Journal:  Nat Cell Biol       Date:  2014-02-23       Impact factor: 28.824

2.  SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms.

Authors:  Stuti Shroff; Asif Rashid; Hua Wang; Matthew H Katz; James L Abbruzzese; Jason B Fleming; Huamin Wang
Journal:  Hum Pathol       Date:  2013-10-19       Impact factor: 3.466

3.  Progenitor cell niches in the human pancreatic duct system and associated pancreatic duct glands: an anatomical and immunophenotyping study.

Authors:  Guido Carpino; Anastasia Renzi; Vincenzo Cardinale; Antonio Franchitto; Paolo Onori; Diletta Overi; Massimo Rossi; Pasquale Bartolomeo Berloco; Domenico Alvaro; Lola M Reid; Eugenio Gaudio
Journal:  J Anat       Date:  2015-11-27       Impact factor: 2.610

4.  Heterogeneous Expression of Embryonal Development Master Regulator SOX9 in Patients with Pancreatic Cancer.

Authors:  L G Kondratyeva; I P Chernov; M V Zinovyeva; V I Egorov; E P Kopantzev; E D Sverdlov
Journal:  Dokl Biochem Biophys       Date:  2018-08-31       Impact factor: 0.788

5.  Exploring the Functional Disorder and Corresponding Key Transcription Factors in Intraductal Papillary Mucinous Neoplasms Progression.

Authors:  Guiying Bai; Chenxuan Wu; Yingtang Gao; Guiming Shu
Journal:  Int J Genomics       Date:  2015-09-03       Impact factor: 2.326

6.  Neat1 is a p53-inducible lincRNA essential for transformation suppression.

Authors:  Stephano S Mello; Carolyn Sinow; Nitin Raj; Pawel K Mazur; Kathryn Bieging-Rolett; Daniela Kenzelmann Broz; Jamie F Conklin Imam; Hannes Vogel; Laura D Wood; Julien Sage; Tetsuro Hirose; Shinichi Nakagawa; John Rinn; Laura D Attardi
Journal:  Genes Dev       Date:  2017-07-11       Impact factor: 11.361

7.  Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.

Authors:  Felix C Popp; Marie Christine Popp; Yue Zhao; Christopher Betzler; Siegfried Kropf; Benjamin Garlipp; Christoph Benckert; Thomas Kalinski; Hans Lippert; Christiane J Bruns
Journal:  BMC Cancer       Date:  2017-03-29       Impact factor: 4.430

8.  Knockdown of SOX9 Inhibits the Proliferation, Invasion, and EMT in Thyroid Cancer Cells.

Authors:  Jie Huang; Li Guo
Journal:  Oncol Res       Date:  2017-01-26       Impact factor: 5.574

9.  SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression.

Authors:  Estefania Carrasco-Garcia; Lidia Lopez; Veronica Moncho-Amor; Fernando Carazo; Paula Aldaz; Manuel Collado; Donald Bell; Ayman Gaafar; Eva Karamitopoulou; Alexandar Tzankov; Manuel Hidalgo; Ángel Rubio; Manuel Serrano; Charles H Lawrie; Robin Lovell-Badge; Ander Matheu
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

10.  Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients' prognosis.

Authors:  Haibo Zhu; Jie Tang; Mingjie Tang; Haikang Cai
Journal:  Diagn Pathol       Date:  2013-11-04       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.